Semaglutide is one of several GLP-1 medications available
Wegovy delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new data at the European Congress on Obesity Novo Nordisk Novo Nordisk announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond
Given semaglutides ability to delay gastric emptying and suppress appetite [5], along with the intragastric balloons space-occupying mechanism, this treatment approach may exhibit a synergistic effect on weight loss
This is where semaglutide belongs
If you are experiencing new, worsening, or concerning symptoms while on a GLP-1 medication, confirm with a licensed clinician, especially if symptoms are persistent or affecting your daily life